A single endoscopic procedure cut six-month weight regain to 5.1% from 8.2% with sham after patients stopped tirzepatide, Fractyl Health…
Zealand Pharma will pay Generate Biomedicines $30M upfront, with total milestones approaching $1.2B, for machine-designed protein drugs aimed at obesity,…
The Hong Kong-listed biotech used its generative chemistry platform to design ISM1354, a small-molecule GIPR antagonist built for obesity and…
Superluminal Medicines banks $60M to take its AI-designed MC4R obesity drug into Phase 1.